SequelSEC

NANOVIRICIDES, INC. NNVC

Pharmaceutical Preparations · CIK 0001379006 · Fiscal year ends 0630

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2026-06-30
Operating income
-$2.25M
Fiscal year ended 2026-06-30
Free cash flow
-$2.12M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$21.53MMarket value of stock held by non-affiliates, as stated on the cover page for 2024-12-31
Float per share$1.24Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / equity2.9×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2024-12-31, not today, and each multiple below it uses the figures for the fiscal year ending 2025-06-30 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio2.66x19th

NANOVIRICIDES, INC. (NNVC) reported revenue of $0 and net income of -$2.22M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from NANOVIRICIDES, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

NANOVIRICIDES, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$0$0$0$0$0$0$0$0$0$0
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$2.25M-$2.03M-$2.23M-$1.80M-$2.12M-$2.25M-$2.06M-$3.17M-$2.39M-$1.91M
Net income-$2.22M-$1.99M-$2.22M-$1.79M-$2.10M-$2.22M-$2.03M-$3.13M-$2.36M-$1.85M
Research & development$1.31M$1.29M$1.12M$993.07K$1.18M$1.28M$1.16M$1.93M$1.18M$1.21M
Weighted-average diluted sharesUnavailableshares 21.61Mshares 19.85Mshares 17.08MUnavailableshares 16.03Mshares 14.57Mshares 13.72MUnavailableshares 11.78M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPSUnavailable$-0.09$-0.11$-0.10Unavailable$-0.14$-0.14$-0.23Unavailable$-0.16
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$936.32K$744.28K$1.11M$803.62K$938.20K$966.90K$902.70K$1.23M$1.21M$693.74K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

NANOVIRICIDES, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$2.79M$3.21M$5.15M$1.13M$1.56M$2.54M$3.96M$3.87M$4.80M$3.26M
Total assets$9.87M$10.22M$12.27M$8.36M$8.82M$10.03M$11.57M$11.74M$12.82M$11.46M
Current assets$3.16M$3.38M$5.30M$1.25M$1.67M$2.73M$4.07M$4.04M$4.97M$3.52M
Total liabilities$1.20M$1.10M$1.20M$1.20M$1.30MUnavailable$1.20M$1.63M$1.36M$813.34K
Current liabilities$1.19M$1.07M$1.20M$1.18M$1.31M$1.20M$1.18M$1.63M$1.36M$813.34K
Total equity incl. NCI$8.68M$9.15M$11.07M$7.17M$7.52M$8.83M$10.39M$10.11M$11.46M$10.65M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

NANOVIRICIDES, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$2.12M-$1.93M-$2.05M-$1.59M-$1.70M-$1.99M-$2.19M-$2.59M-$1.48M-$1.94M
Capital expenditures$1$0-$1$84.32K$10.20K$0$0$46.76K$98.16K$44.63K
Investing cash flow-$1$0$1-$84.32K-$10.20K$0$0-$46.76K-$98.16K-$44.63K
Financing cash flow$1.70M-$6.74K$6.07M$1.25M$728.08K$575.50K$2.28M$1.71M$3.12M$0
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

NANOVIRICIDES, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$2.12M-$1.93MUnavailable-$1.68M-$1.71M-$1.99M-$2.19M-$2.64M-$1.58M-$1.99M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio2.66x3.17x4.43x1.06x1.28x2.27x3.44x2.48x3.66x4.32x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NNVC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-K · Filed 2026-09-28View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-Q · Filed 2026-02-17View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-K · Filed 2025-09-29View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.